Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This is a 16-week research study in which participants suffering from Social Anxiety Disorder
(SAD) will receive Sertraline (a medication FDA approved for the treatment of SAD) for the
first 8 weeks. If a participant remains symptomatic, he/she will enter the second phase of
the study in which he/she continues taking Sertraline but also randomly receives either
Seroquel or placebo in conjunction with Sertraline for additional 8 weeks. The purpose of
this study is to determine the efficacy of adjunctive Seroquel in treating SAD.